Etranacogene Dezaparvovec: 9 agencies, 2023–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused etranacogene dezaparvovec: all 8 decisive outcomes across 8 agencies were positive or positive with restrictions.
The record spans 2.1 years, opening at HAS (France) on 30 Aug 2023 and running to 4 Sep 2025.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 9 of 9 records date from 2023 or later.
3 distinct indication wordings are recorded for etranacogene dezaparvovec by the agencies that label one in English (AWMSG, NICE and SMC).
HAS (France) was first to assess etranacogene dezaparvovec, on 30 Aug 2023; AIFA (Italy) did not open a file until 4 Sep 2025 — a moderate spread of 2.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 9 dated records fall in 2024 alone.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed etranacogene dezaparvovec to a subgroup rather than accepting or refusing it outright, at G-BA (Germany) and NICE (England).
9 of the 18 agencies in this archive hold a record for etranacogene dezaparvovec.
The full ledger for etranacogene dezaparvovec reads 6 recommended, 2 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AIFA (Italy) | 4 Sep 2025 | Hemgenix è indicato per il trattamento dell'emofilia B (deficit congenito del fattore IX) severa e moderatamente severa … | fully innovative · reimbursed class H | source |
| CIPM (Spain) | 26 Sep 2024 | SECRETARIA DE ESTADO DE SANIDAD 7 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicación terapéutica autorizada: Hemgeni… | financed by the SNS · art. 92 a, c | source |
| SMC (Scotland) | 12 Aug 2024 | For treatment of severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. | accepted | source |
| NICE (England) | 24 Jul 2024 | NICE TA989 | recommended (optimised) | source |
| ZIN (Netherlands) | 15 Jul 2024 | Advies - vergoed etranacogene dezaparvovec (Hemgenix®) voor de behandeling van hemofilie B | reimbursed (sluis) | source |
4 further decisions for etranacogene dezaparvovec, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- emicizumab — same ATC class B02B — Antihemorrhagics
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- marstacimab — same ATC class B02B — Antihemorrhagics
Coverage: 9 decisions for etranacogene dezaparvovec from 9 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.